For research use only. Not for therapeutic Use.
Ranolazine-d3 (CAS: 1054624-77-9), a premium pharmaceutical research compound designed for advanced cardiovascular studies. As a deuterated analog of Ranolazine, it offers enhanced stability and improved pharmacokinetic properties. Ranolazine-d3 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel cardiovascular therapies. Trusted by leading laboratories, Ranolazine-d3 is your go-to solution for cutting-edge cardiovascular research. Unlock new possibilities in heart disease treatment with Ranolazine-d3, where innovation meets reliability.
| Catalog Number | S000261 |
| CAS Number | 1054624-77-9 |
| Molecular Formula | C24H30D3N3O4 |
| Purity | ≥95% |
| IUPAC Name | N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-[2-(trideuteriomethoxy)phenoxy]propyl]piperazin-1-yl]acetamide |
| InChI | InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29)/i3D3 |
| InChIKey | XKLMZUWKNUAPSZ-HPRDVNIFSA-N |
| SMILES | [2H]C([2H])([2H])OC1=CC=CC=C1OCC(CN2CCN(CC2)CC(=O)NC3=C(C=CC=C3C)C)O |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Keating GM. Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris. Drugs. 2013 Jan;73(1):55-73. [3]. Wang WQ, et al. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81. [4]. Zacharowski K, et al. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10. |
